United-Guardian Inc

United-Guardian Inc(UG)股票分析

$7.150

-0.049 (-0.69%)收盘时

Loading chart…
High
7.398
Open
7.250
VWAP
7.22
Vol
9.38K
Mkt Cap
42.64M
Low
7.120
Amount
67.71K
EV/EBITDA, TTM
0.00

United-Guardian, Inc. is a manufacturer of cosmetic ingredients, sexual wellness ingredients, pharmaceuticals, and medical lubricants. The Company’s product lines include the Lubrajel line of multifunctional hydrogel formulations, which are designed to provide sensory enhancement, lubrication, hydration, and texture to both personal care and medical products. Its four distinct product categories include cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. Its COSMOS line of products includes Lubrajel Natural, Lubrajel Marine, Lubrajel Oil Natural, and Lubrajel Terra. Its medical lubricants include a line of hydrogel formulations designed to offer sensory enhancement and lubrication to medical products. The Company’s pharmaceutical products include an FDA-approved prescription drug that is used primarily to prevent and to dissolve calcifications in urethral catheters, as well as a chlorine-based topical antimicrobial.

u-g.com

AI analysis of United-Guardian Inc (UG)

hold

United-Guardian Inc is currently not a strong buy due to mixed signals in its performance and market conditions. The stock's current price is $7.15, with a forward P/E ratio of 26.53 indicating potential overvaluation compared to its historical performance. Additionally, the RSI is at 45.37, suggesting the stock is neither overbought nor oversold, which implies caution for new investors. The main risk is the recent decline in revenue by 13.5% year-over-year, reflecting challenges in the market environment, which could impact future profitability.

估值指标

The current forward P/E ratio for United-Guardian Inc (UG) is 26.53, compared to its 5-year average forward P/E of 3.58.

Forward P/E

Strongly Overvalued
5Y Average P/E
3.58
Current P/E
26.53
高估
12.76
低估
-5.61

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
高估
0.00
低估
0.00

Forward P/S

Strongly Undervalued
5Y Average P/S
0.00
Current P/S
0.00
高估
0.00
低估
0.00

Alphio AI Price Scenarios for UG

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%UG

$13.06

情景价格

B

Base

Base · 50%UG

$11.05

情景价格

B

Bear

Bear · 25%UG

$10.96

情景价格

事件时间线

2025-11-06 (ET)

09:04:50

United-Guardian Announces Q3 Earnings Per Share of 6 Cents Compared to 19 Cents Last Year

2025-08-08 (ET)

09:05:14

United-Guardian reports Q2 EPS 14c vs 21c

2025-05-21 (ET)

09:05:44

United-Guardian appoints Donna Vigilante to board of directors

2025-05-08 (ET)

09:03:12

United-Guardian reports Q1 EPS 12c vs 20c last year

2025-03-21 (ET)

09:04:32

United-Guardian reports FY24 EPS 71c vs 56c last year

资讯

UG FAQ — answered by Alphio AI

United-Guardian, Inc. is a manufacturer of cosmetic ingredients, sexual wellness ingredients, pharmaceuticals, and medical lubricants. The Company’s product lines include the Lubrajel line of multifunctional hydrogel formulations, which are designed to provide sensory enhancement, lubrication, hydration, and texture to both personal care and medical products. Its four distinct product categories include cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. Its COSMOS line of products includes Lubrajel Natural, Lubrajel Marine, Lubrajel Oil Natural, and Lubrajel Terra. Its medical lubricants include a line of hydrogel formulations designed to offer sensory enhancement and lubrication to medical products. The Company’s pharmaceutical products include an FDA-approved prescription drug that is used primarily to prevent and to dissolve calcifications in urethral catheters, as well as a chlorine-based topical antimicrobial. It operates in the Healthcare sector (PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS industry).

United-Guardian Inc is currently not a strong buy due to mixed signals in its performance and market conditions. The stock's current price is $7.15, with a forward P/E ratio of 26.53 indicating potential overvaluation compared to its historical performance. Additionally, the RSI is at 45.37, suggesting the stock is neither overbought nor oversold, which implies caution for new investors. The main risk is the recent decline in revenue by 13.5% year-over-year, reflecting challenges in the market environment, which could impact future profitability.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始